- Conditions
- Clostridium Difficile Infection Recurrence
- Interventions
- RBX2660
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 41 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 12
- States / cities
- North Little Rock, Arkansas • Camarillo, California • Hamden, Connecticut + 9 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Clostridium Difficile Infection, Infection, Communicable Diseases
- Interventions
- RBX2660
- Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 793 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 46
- States / cities
- Phoenix, Arizona • North Little Rock, Arkansas • Oxnard, California + 43 more
- Conditions
- Recurrent Clostridium Difficile Infection
- Interventions
- RBX2660 (microbiota suspension)
- Biological
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 13
- States / cities
- Phoenix, Arizona • Denver, Colorado • Jacksonville, Florida + 8 more
- Conditions
- Enterocolitis Clostridium Difficile Recurrent
- Interventions
- RBX2660 (microbiota suspension), Placebo
- Biological · Other
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 19
- States / cities
- Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 15 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- RBX2660, Standard of Care Antibiotics
- Biological · Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 272 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 28
- States / cities
- Phoenix, Arizona • North Little Rock, Arkansas • Sacramento, California + 25 more
- Conditions
- Urinary Tract Infections
- Interventions
- Fecal microbiota transplant
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Clostridium Difficile Infection (CDI)
- Interventions
- RBX2660, Placebo, Open label RBX2660 (only for confirmed CDI recurrence)
- Drug
- Lead sponsor
- Rebiotix Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 320 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 60
- States / cities
- Athens, Alabama • Dothan, Alabama • Phoenix, Arizona + 54 more